A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis (DUET ENCORE-UC)
78934804UCO3001: A Phase 3 Randomized, Double-blind, and Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Colitis, Ulcerative
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 644
- Started
- 23 May 2026
- Main results due (estimated)
- 11 August 2028
- Study ends (estimated)
- 16 October 2030
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Double (participant, investigator)
- Sites
- 318 · 8 in India
- First posted
- 11 May 2026
- Registry updated
- 3 November 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion criteria: * Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC. * Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy * An endoscopy subscore \>=2 as obtained during central review of the screening video endoscopy * Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies Exclusion criteria: * Isolated proctitis (UC limited to the rectum only or to less than \[\<\] 20 centimeter \[cm\] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis * Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD * Has a history of or ongoing chronic or recurrent infectious disease * Has previously demonstrated inadequate initial response, loss of response, allergy, hypersensitivity or intolerance to guselkumab or to golimumab * Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
What participants receive
- Experimental
JNJ-78934804
Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.
Drug: JNJ-78934804
- Active comparator
Guselkumab
Participants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.
Drug: JNJ-78934804 · Drug: Guselkumab
Interventions
JNJ-78934804Drug
Also known as JNJ-4804
JNJ-78934804 will be administered subcutaneously.
GuselkumabDrug
Also known as TREMFYA
Guselkumab will be administered subcutaneously.
What the study measures
Primary outcomes
Percentage of Participants in Clinical Remission at Week 48
Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1.
Time frame: At Week 48
Secondary outcomes
Percentage of Participants with Endoscopic Improvement at Week 48
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Time frame: At Week 48
Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48
Corticosteroid-free (90 day) clinical remission is defined as clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.
Time frame: At Week 48
Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Histologic remission is defined as an absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system.
Time frame: At Week 48
Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48
Fatigue response is defined as a greater than or equal to (\>=) 7- point reduction in the patient-reported outcomes measurement information system (PROMIS) fatigue short form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).
Time frame: At Week 48
Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0
Percentage of participants with a SF subscore of 0 or 1 and RB subscore of 0 at three assessment time points of Week 12, Week 24, and Week 48 will be reported.
Time frame: At Weeks 12, 24, and 48
Percentage of Participants in Abdominal Pain Remission at Week 48
Percentage of participants in abdominal pain remission at week 48 will be reported.
Time frame: At Week 48
Change From Baseline in Abdominal Pain Score at Week 48
Change from baseline in abdominal pain score based on abdominal pain-numerical rating scale (AP-NRS) will be reported. NRS is 11 point (0 to 10) scoring system used to evaluate abdominal pain. The score of 0 represents "no pain" and the score of 10 represents "pain as bad as you can imagine", with greater scores indicating greater pain severity and intensity.
Time frame: Baseline and Week 48
Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48
IBDQ response is defined as improvement from baseline in the total IBDQ score of \>= 16 points. The IBDQ is a 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).
Time frame: At Week 48
Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48
PROMIS 29 MCS response is defined as a \>= 7-point improvement from baseline in PROMIS 29 MCS response at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.
Time frame: At Week 48
Percentage of Participants in Clinical Remission at Week 12
Clinical remission is defined as an SF subscore of 0 or 1, RB subscore of 0, and an endoscopy subscore of 0 or 1.
Time frame: At Week 12
Percentage of Participants with Endoscopic Improvement at Week 12
Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Time frame: At Week 12
Percentage of Participants with Mayo SF/RB Response at Week 2
Mayo SF/RB response is defined as a decrease from baseline in the sum of the SF and the RB subscores by \>=30 percent (%) and \>= 1 point, with either a \>= 1 point decrease from baseline in the RB subscore or an RB subscore of 0 or 1.
Time frame: At Week 2
Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.
Time frame: Up to approximately 3 years
Who is running it
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Janssen Research & Development, LLC
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- 78934804UCO3001
- Other IDs
- 78934804UCO3001, 2026-525923-26-00
Janssen Research & Development, LLC Clinical Trial
Study director
Janssen Research & Development, LLC
Study sites(318)
Sushruta Multispecialty Hospital and Research Centre
Hubli, India
Recruiting
Asian Institute Of Gastroenterology
Hyderabad, India
Recruiting
S. R. Kalla Memorial General Hospital
Jaipur, India
Recruiting
Lisie Hospital
Kochi, India
Recruiting
P D Hinduja National Hospital and Medical Research Center
Mumbai (ex Bombay), India
Recruiting
Yashoda Super Speciality Hospitals
Secunderabad, India
Recruiting
SIDS Hospital & Research Centre
Surat, India
Recruiting
Gujarat Gastro and Vascular Hospital
Surat, India
Recruiting
Mayo Clinic
Scottsdale, Arizona, United States
Recruiting
GIA Sun City
Sun City, Arizona, United States
Recruiting
Clinnova Research
Anaheim, California, United States
Recruiting
Gastro SB Clinic
Chula Vista, California, United States
Recruiting
United Medical Doctors
Los Alamitos, California, United States
Recruiting
Medical Associates Research Group, Inc.
San Diego, California, United States
Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Recruiting
Florida Research Center Inc.
Lakewood Rch, Florida, United States
Recruiting
Sanchez Clinical Research, Inc
Miami, Florida, United States
Recruiting
Endoscopic Research Inc
Orlando, Florida, United States
Recruiting
GCP Clinical Research
Tampa, Florida, United States
Recruiting
Atlanta Gastroenterology Specialists
Suwanee, Georgia, United States
Recruiting
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky, United States
Recruiting
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana, United States
Recruiting
GIA Metairie
Metairie, Louisiana, United States
Recruiting
GIA Kansas City
Lee's Summit, Missouri, United States
Recruiting
New York Gastroenterology Associates
New York, New York, United States
Recruiting
University of North Carolina Hospital
Chapel Hill, North Carolina, United States
Recruiting
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, United States
Recruiting
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma, United States
Recruiting
The Oregon Clinic
Portland, Oregon, United States
Recruiting
Michigan Center of Medical Research
Farmington Hill, Pennsylvania, United States
Recruiting
Frontier Clinical Research
Uniontown, Pennsylvania, United States
Recruiting
Palmetto Primary and Specialty Care Physicians, Charleston
Summerville, South Carolina, United States
Recruiting
Gastro One
Cordova, Tennessee, United States
Recruiting
Southern Star Research Institute, LLC
San Antonio, Texas, United States
Recruiting
Tyler Research Institute, LLC
Tyler, Texas, United States
Recruiting
GIA Webster
Webster, Texas, United States
Recruiting
GIA Richmond
Richmond, Virginia, United States
Recruiting
GI Alliance Tacoma
Tacoma, Washington, United States
Recruiting
Instituto Medico De Alta Complejidad (IMAC)
Buenos Aires, Argentina
Recruiting
GEDYT
Famailla, Argentina
Recruiting
Showing 40 of 318 sites. 318 recruiting, 0 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Source: ClinicalTrials.gov record NCT07577856, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.